Inactive Instrument

ONCODESIGN

Equities

ALONC

FR0011766229

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Oncodesign Société Anonyme(ENXTPA:ALONC) dropped from Next Biotech Index CI
Oncodesign Services Names Successors as Chairman/CEO Departs MT
Oncodesign Services Shareholders Sell Majority Stake to Edmond de Rothschild Fund MT
Oncodesign Precision Medicine to List Directly on Euronext Access + Paris MT
Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme. CI
Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme. CI
Oncodesign Unit Gains Approval To List On Euronext Access + In Paris MT
Oncodesign Société Anonyme agreed to Spin-Off Oncodesign Precision Medicine. CI
Oncodesign Société Anonyme Announces Planned Separation of Its Two Business Areas CI
Oncodesign Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Sengine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors CI
Oncodesign Société Anonyme Reports Turnover Results for the Year Ended December 31, 2021 CI
Oncodesign Société Anonyme's Equity Buyback announced on February 15, 2021, has expired. CI
Oncodesign Strengthens the Intellectual Property of ODS 101 in Treating Inflammatory Bowel Disease CI
Oncodesign : Appoints Chief Development Officer MT
Oncodesign Appoints Karine Lignel as Group Chief Development Officer CI
Oncodesign : Starts R&D Deal with TiumBio for Fibrosis Drug Candidates MT
Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates CI
Oncodesign Announces Unaudited Consolidated Sales Results for the Half Year Ended June 30, 2021 CI
Global markets live: AT&T, American Airlines, Biogen, Netflix, ABB... Our Logo
Oncodesign Announces Unaudited Consolidated Turnover Results for the First Half of 2021 CI
Oncodesign Appoints Aline Aubertin as New Independent Director CI
Oncodesign Announces a Strategic Collaboration Agreement with Covalab CI
Global markets live: Siemens, BHP Group, Visa, JP Morgan Chase, Proximus... Our Logo
Oncodesign Provides Update on Its Progress on RIPK2 CI
Chart ONCODESIGN
More charts
ONCODESIGN specializes in preclinical pharmacological evaluation services of new cancer therapies on behalf of the pharmaceutical and biotechnological companies. The group also provides research and development of drugs and biomarkers primarily for the treatment of cancer. The group's activity is organized around 3 business units: - Service: discovery, identification and selection of new therapeutic targets in oncology; - Biotech: development of a portfolio of therapeutic and diagnostic projects alone or through partnerships; - Artificial Intelligence: development of a platform for selecting new therapeutic targets in oncology. 60.3% of sales are abroad.
More about the company
  1. Stock
  2. Equities
  3. Stock ONCODESIGN - Euronext Paris
  4. News ONCODESIGN
  5. Oncodesign : Appoints Chief Development Officer